Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors (Q33361997)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors |
scientific article |
Statements
1 reference
Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors (English)
1 reference
Mark J Ratain
1 reference
Nicholas J Vogelzang
1 reference
Samir D Undevia
1 reference
Ann M Mauer
1 reference
Linda Janisch
1 reference
Sridhar Mani
1 reference
1 November 2004
1 reference
1 reference
22
1 reference
449-458
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference